Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The immune response targeting hepatitis B surface antigen (HBsAg) is crucial for preventing and controlling hepatitis B virus (HBV) infection. Vaccination with HBsAg induces protective anti-HBs antibodies, primarily through B cell activation supported by T cell immunity. Effective clearance or control of HBV requires robust adaptive immunity.
Induction of anti-HBs antibodies through B cell activation and T cell help, leading to neutralization of circulating HBV particles and prevention of infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune system (antibody induction against HBsAg).